Source: GlobalNewswire

Press Release: Karyopharm : ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action - KPTI

NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the "Class Period"); (ii) in or traceable to Karyopharm's public offering of common stock conducted on or around April 28, 2017; or (3) in or traceable to Karyopharm's public offering of common stock conducted on or around May 7, 2018, of the important September 23, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Karyopharm's latest SEC filings

Annual Revenue

Based on data from Karyopharm's latest SEC filings

Employees

Michael G. Kauffman's photo - Co-Founder & CEO of Karyopharm

Co-Founder & CEO

Michael G. Kauffman

CEO Approval Rating

68/100

Karyopharm researches and develops therapeutics for the treatment of cancer.

Karyopharm's headquarters is in Newton, Mass...
Read more